title: Systematic correlation of morphologic alterations and retinal function in eyes with uveitis-associated cystoid macular oedema during development, resolution and relapse.
abstract: OBJECTIVE
  To evaluate morphological changes due to uveitis-associated cystoid macular oedema (uvCME) and their impact on central retinal sensitivity (CRS) before and after intravitreal triamcinolone-acetonide (IVTA).
  
  
  METHODS
  28 eyes with uvCME were examined with microperimetry and spectral-domain optical-coherence-tomography (SD-OCT) before and after IVTA. Microperimetry-maps were superimposed on SD-OCT and morphological-alterations were correlated point to point with CRS and followed-up for 3 months. The effects of morphological-alterations on CRS over time were evaluated with a linear mixed-model.
  
  
  RESULTS
  Mean-CRS increased significantly after IVTA (p=0.009). Proportion of cysts correlated negatively with corresponding CRS (estimate/95% CI -3.8 dB/-6.6 to -0.9, p=0.011). Proportion of diffuse macular-oedema (DifME) had no significant effect on mean-CRS (-0.76 dB/-4.9 to 3.3, p=0.71). The proportion of serous retinal detachment (SRD) had a borderline significant effect on mean-CRS (-9.5 dB/-19.1 to 0.1, p=0.052), however the initial presence of SRD at baseline had no significant negative effect on mean-CRS (-1.3 dB/-4.9 to 2.3, p=0.46). Patients with epiretinal-membrane showed lower mean-CRS than patients without (-3.3 dB/-6.5 to -0.008, p=0.05). The lowest percentage of morphological-alterations was achieved 30 days post IVTA concordant to best visual-acuity (logMAR 0.16 ± 0.26), while best mean-CRS was achieved 90 days post IVTA (16.9 ± 1.8 dB). Fixation-stability showed no significant improvement.
  
  
  CONCLUSIONS
  UvCME Morphological-alterations were associated with specific CRS-decreases. DifME showed no significant- and SRD only a borderline effect on mean-CRS, which implicates that their presence should be considered when interpreting SD-OCT and making treatment-decisions.
authors.affiliation: Department of Ophthalmology, Medical University of Vienna, , Vienna, Austria.
authors.forename: Marion R
authors.initials: MR
authors.lastname: Munk
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Kiss
authors.forename: Irene
authors.initials: I
authors.lastname: Steiner
authors.forename: Florian
authors.initials: F
authors.lastname: Sulzbacher
authors.forename: Phillipp
authors.initials: P
authors.lastname: Roberts
authors.forename: Maria
authors.initials: M
authors.lastname: Kroh
authors.forename: Alessio
authors.initials: A
authors.lastname: Montuoro
authors.forename: Christian
authors.initials: C
authors.lastname: Simader
authors.forename: Ursula
authors.initials: U
authors.lastname: Schmidt-Erfurth
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D041623:Tomography, Optical Coherence / Q000379:methods; D014221:Triamcinolone / Q000627:therapeutic use; D014605:Uveitis / Q000150:complications* / Q000188:drug therapy; D014792:Visual Acuity / Q000502:physiology; D058609:Visual Field Tests; D014794:Visual Fields / Q000502:physiology
chemical_list: D000893:Anti-Inflammatory Agents; D014221:Triamcinolone
keywords: Imaging; Macula; Treatment Medical